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Objectives. To determine the prevalence of incidentalomas in a patient population with no known thyroid malignancy who
underwent whole body FDG-PET/CT for staging or restaging of neoplasia. The additional aim of the study was to evaluate the
feasibility of using PETCT as a screening tool for malignant thyroid incidentalomas. Methods. Retrospective review of medical
records of all the thyroid exams done at our institution between January 1, 2000 and August 20, 2008. We made a criterion of
PET/CT as the primary method of detection of incidentalomas. Results. From a total of 8464 thyroid exams, 156 incidentalomas
were found and 40 incidentalomas underwent anatomopathology analysis, which was used as gold standard. Chi-square analysis
was used to analyze the data. There is no signiﬁcant association between SUV value and the prevalence of incidentalomas.
Discussion. From January 1, 2000 to August 20, 2008, incidentalomas have a prevalence of 1.84% at our institution. 38% of the
incidentalomas that were biopsied were characterized as representing malignant tumors. Conclusion. Focal, abnormal FDG uptake
representing incidentalomas must be followed up with biopsies. It is impractical to use PET/CT as a screening tool to detect
incidentalomas for the general population but it must be done in patients with history of any type of cancer.
1.Introduction
Thyroid incidentalomas are newly detected thyroid nodules,
discovered during a computed tomography (CT), magnetic
resonance imaging (MRI), ultrasound (US), or positron
emission tomography (PET) exam for nonthyroid diseases.
They are divided into focal and diﬀuse types. Focal type is
deﬁned as an area of uptake of 2-ﬂuorodeoxyglucose (FDG)
in less than one lobe, whereas diﬀuse type is FDG uptake in
the entire thyroid gland. There are guidelines for managing
palpable thyroid nodules but there are no such guidelines for
nonpalpable nodules [1].
FDG-PET has a reported sensitivity of 75–90% and a
speciﬁcity of 90% for detecting thyroid malignancies [2].
Whole body FDG-PET/CT combines the technology of
whole body CT scan with FDG uptake localization to assess
glucose utilization rates. The vast majority of solid tumors
have an enhanced glycolytic rate, and they are therefore
amenable of being imaged with FDG-PET. FDG-PET has
become the standard of practice for staging, restaging, and
assessment of therapy response in a variety of malignant
solid tumors. Normal thyroid gland shows very low FDG
uptake,andsomedatasuggestthatamoderatediﬀuseuptake
can represent a normal variant [3]. However, FDG has
high accumulation in tumors because of increased glucose
transport and glycolysis. Benign diseases of the thyroid such
as Graves’ disease and thyroiditis can have high standard
uptake values (SUV) because of increased blood ﬂow,
increased glucose metabolism, autoimmune response by
lymphocytes, and inﬂammation [4]. Moreover, Hurthle cell
adenomas generally show increased FDG avidity. Therefore,
areaswithhighFDGuptakecanbenonspeciﬁcandcanrange
from benign processes to malignant neoplasms. Thyroid
n o d u l e sh a v ed i ﬀerent morphologic appearances, and they
canbeseenasdiﬀuseorfocusedlesionsonthePET/CT.Focal
FDG uptake in the thyroid has a reported malignancy rate of
25–50% [4].2 International Journal of Molecular Imaging
Table 1: Risk factors for thyroid malignancy [2].
Risk factors for thyroid malignancy
(1) Previous irradiation
(2) Age <20 or >60 years
(3) Male
(4) History of cancer
(5) Family history of thyroid cancer
(6) Rapid growth
(7) Hard nodule
(8) Single nodule
(9) Size > 4cm
(10) Cervical lymphadenopathy
(11) Vocal cord palsy
The management of thyroid incidentalomas is inhomo-
geneous. US is usually the ﬁrst step in the management
of thyroid abnormalities found in physical and laboratory
exams. The overall incidence of thyroid incidentalomas is on
the rise with 2.4 times increase in the last decade [1].
Based on the PET/CT alone, deﬁnite diagnosis cannot
be made since there are no established criteria to diagnose
benign or malignant incidentalomas. Current practice is to
biopsy all nodules >1cm and all nodules <1cm with risk
factors for malignancy [1]. This study also aims to assess the
value of PET/CT as a screening tool to screen for thyroid
incidentalomas. There is no report on the prevalence of
PET/CT thyroid incidentalomas in the general population
[5]. Yet, thyroid incidentalomas are quite common, and their
prevalence depends on the population studied, region or
country where the study was conducted, and the diagnostic
methods used [6].
2. Methods
We performed a retrospective analysis of all whole body
FDG-PET/CT done at our institution between 1/1/2000
and 8/20/2008 (Figure 1). An inclusion criteria was that
the lesions were not visible or palpable during routine
clinical exam. We excluded from our study all cases with
prior histories of thyroid neoplasms and thyroidectomies
or any type of thyroid surgery. Risk factors for developing
thyroid neoplasms are mentioned in Table 1. Patients with
histories of benign thyroid diseases were also included.
Anatomopathologic diagnosis was used as a gold standard.
A total of 156 patients who had abnormal FDG uptake were
further selected for secondary analysis. From this group,
40 patients who had biopsy reports were selected as the
ﬁnal study population. This retrospective clinical study was
approved by the local IRB.
2.1. Statistical Analysis. Mean values are given with standard
deviations. Comparison of proportions was made by chi-
square analysis. Univariate one-way analysis of variance
(ANOVA)wasperformedtocharacterizediﬀerencesbetween
segments classiﬁed according to the results of diagnostic
156 studies with abnormal FDG uptake
40 patients who had biopsy reports
All thyroid exams done at UCSF
from 1/1/2000 to 8/20/2008
8464 total
Figure 1: Flowchart of the procedures to choose the ﬁnal study
population.
methods. A P value of <0.05 was considered statistically
signiﬁcant.
3. Results
In this study, only 40 out of 156 incidentalomas (25.6%) had
biopsies. The sizes of the lesions ranged from 2mm to 6cm.
There are lesions with low, hyperdense, and a mixture of low
and high attenuations. SUV values range from 0.8 to 46. The
results of our study are described in detail in Table 2.O u r
results show no correlation between the size of the lesion and
the SUV value. There are papers that show the correlation
between size and SUV value while some show no correlation
[3].
In the group of cancerous incidentalomas, there are 6
males (mean age 53.3, age range 33–78) and 9 females
(mean age 56.2, age range 38–73). For the group with benign
incidentalomas, there are 4 males (mean age 76.5, age range
69–83) and 21 females (mean age 59.1, age range 39–86).
14 out of 15 (93%) malignant lesions have focal uptake, and
the remaining 1 has diﬀuse uptake. This ﬁnding agrees with
prior studies in that focal uptake lesions have >30% increase
in malignancy rates compared to diﬀuse uptake lesions [1].
Among cancerous nodules, the highest SUV value is 9.9
and the lowest is 2.5 (Figure 2), and for the benign lesions,
the highest is 46 and the lowest is 0.8. From the 40 biopsy
reports, there are 15 cancerous nodules, corresponding to
about 38%. There are 11 papillary carcinomas (6 right lobe,
3 left lobe, 2 both lobes), 1 follicular carcinoma (left lobe),
1 anaplastic carcinoma (right lobe), 1 adenocarcinoma from
the breast primary (left lobe), and 1 metastasis of unknown
origin (right lobe). Among benign incidentalomas, there are
2 nonspeciﬁc benign lesions (1 left lobe and 1 right lobe),
18 colloid lesions (10 left lobe and 8 right lobe), 1 chronicInternational Journal of Molecular Imaging 3
Table 2: PETCT and biopsy results of 40 patients at UCSF.
Patient number, age & sex Size (cm,mm) Focal/diﬀuse SUV Biopsy
(1) 40, F 0.6cm Focal 2.9 papillary ca, right lower thyroid
(2) 73, M 1cm Focal 7.8 thyroid epithelium in nonspeciﬁc pattern, left thyroid gland
(3) 66, M 9 ∗ 6mm N/A 7.5 papillary ca, left thyroid lobe
(4) 42, F 2.2cm Focal 5.3 benign nodule:left anterior, left posterior:follicular
neoplasm
(5) 49, F 2.4cm Focal 3.2 benign colloid, right thyroid gland
(6) 59, F 8mm Focal 3 benign nodule, left thyroid lobe
(7) 52, F 4-5cm Focal 9.9 papillary ca, right thyroid
(8) 39, F 1.6cm Diﬀuse 4 chronic lymphocytic thyroiditis, right thyroid lobe
(9) 49, F 2cm Heterogenous 1.7 benign nodule, left thyroid lobe
(10) 61, F 1.6cm on Right N/A 3 right:thyroid epithelium in nonspeciﬁc pattern, left:benign
thyroid nodule
(11) 65, F 1cm Focal 6.7 papillary ca, left thyroid lobe
(12) 56, F 1cm Diﬀuse 4.8 no ca identiﬁed, left thyroid lobe
(13) 54, F N/A Heterogenous 1.9 benign nodule, left thyroid lobe
(14) 33, M 13mm Focal 5.6 papillary ca, right thyroid
(15) 62, F N/A Heterogenous 0.8 thyroid epithelium in nonspeciﬁc pattern, left thyroid gland
(16) 58, F N/A Heterogenous 5.6 benign nodule:left lobe, right lobe:no bx, suv 5.6
(17) 75, F 2cm Focal 3.2 follicular lesion, adenomatoid nodule, left lobe
(18) 44, F 6mm Focal 3.5 Hurthle cell lesion, path: follicular adenoma, left thyroid
lobe
(19) 78, F 1.9cm Focal 3.7 benign nodule, left thyroid lobe
(20) 64, F 7mm Focal 46 Hurthle cell lesion, right lobe
(21) 78, M N/A Focal 2.9 anaplastic thyroid ca arising from papillary ca in right lobe
(22) 54, F 2mm N/A 5.7 benign nodule, right thyroid lobe
(23) 71, F N/A Diﬀuse 3.6 no ca, right thyroid lobe
(24) 73, F 2.1cm Focal 2.5 met, unknown primary, right inferior thyroid
(25) 63, F N/A Focal 16.4 benign nodule, left lobe
(26) 83, M 9mm Focal 3.8 benign nodule, right thyroid lobe
(27) 54, F 1cm Focal 4 papillary ca in both lobes,
(28) 69, M 2.2cm Focal 3 benign nodule, right thyroid lobe
(29) 56, F 1.8cm Focal 3.4 benign nodule, left lobe
(30) 50, F 1.7 ∗ 1cm Focal 20 follicular adenoma:right lobe SUV 20, left lobe: benign
colloid nodule
(31) 47, M N/A Focal 5.6 papillary ca in both lobes, suv 5.6 in left lobe
(32) 42, F 1.1 ∗ 0.9cm Focal 9.1 papillary ca, left thyroid lobe
(33) 86, F 0.4 ∗ 2.3cm Focal 5.3 benign nodule, left lobe
(34) 53, F 2.3cm Focal 5.3 adenocarcinoma from breast primary, left thyroid
(35) 38, F N/A Focal 7.5 papillary ca, right thyroid
(36) 54, M 9mm Focal 3 papillary ca, right thyroid
(37) 81, M 1.8 ∗ 1.2cm Focal 20 benign nodule, right thyroid lobe
(38) 50, F 6mm Focal 4.8 benign nodule, right thyroid lobe
(39) 42, M 4.1 ∗ 2.5 ∗ 6cm Diﬀuse 5.1 neoplasm, right thyroid
(40) 63, F 13mm Diﬀuse 2.4 benign nodule4 International Journal of Molecular Imaging
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Figure 2: The distribution of SUV values for benign and malignant
lesions.
lymphocytic thyroiditis (right lobe), 3 follicular adenomas
(2 left lobe and 1 right lobe), and 1 Hurthle cell lesion (right
lobe).
4. Discussion
Generally, incidentalomas found in males at young age carry
a risk of being malignant. Studies have revealed that 60%
of the population at age 60 has incidentalomas [1]. Conse-
quently,increasingageisalsoariskfactorforincidentalomas.
We also ﬁnd that incidentalomas are far more common in
females than males, and this is in agreement with other
studies [3]. Framingham population-based study reported
the thyroid nodule prevalence of 6.4% for females versus
1.6% for males [17]. The average size of nodules in the
malignant group (n = 12) is 2.0cm (range 0.6–6cm), and
that in the benign group (n = 20) is 1.4cm (range 0.2–
2.4cm). The graphical representation of sizes in Figure 3
shows that the majority of sizes of benign and malignant
incidentalomas are in the same range (i.e., below 3cm) with
only 2 of the lesions in the malignant group (5cm and 6cm,
resp.) outside this range. We cannot safely conclude that
small nodules are benign and large nodules are cancerous,
and there is no agreement yet on the cutoﬀ value of the size
of the lesion to warrant further workup. Adequate samples
are diﬃcult to obtain from lesions <8mm [2]. On the
other hand, studies have shown that cancer prevalence for
lesions <1a n d>1cm is the same [2], and so we must take
the other risk factors into consideration besides the size.
Moreover, Papini et al. who examined US features of thyroid
nodules also found no correlation between malignancy and
the dimensions of the lesion or the multinodularity [18].
AttenuationisafeatureofCT,andlowattenuationmeans
that a particular area is less intense than the surrounding.
All of the malignant nodules conﬁrmed by biopsy have low
attenuation, with the exception of two which have a mixture
of high and low attenuation. For this study, malignant
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Figure 3: The distribution of size for benign and malignant lesions.
nodules are predominantly associated with low attenuation
on PET/CT. Some studies associate low attenuation with
malignancy while some suggest high attenuation for malig-
nancy [4, 6].
Diﬀuse FDG uptake is often due to hypothyroidism
or thyroiditis, especially Hashimoto’s or autoimmune thy-
roiditis [4]. One study reported higher likelihood of cancer
when the average SUV is greater than 5.69 [6]b u tm o s t
other studies cannot ﬁnd a correlation between SUV and
malignancy [9, 19]. In our study, the average SUV value
of the malignant group (n = 15) is 5.5, and that of the
benign group (n = 25) is 7.2. As a result, considering
these information, we cannot set a threshold SUV value for
malignant lesions. Our prevalence of 38% falls within the
range of 18–50% reported in the literature for prevalence
of malignancy among incidentalomas [20]. In our study,
most of the malignant incidentalomas are primary thyroid
malignancies, and this is similar to other studies where most
cancerousincidentalomasarethyroidprimary[21].Papillary
carcinomas are most common, and the majority of them
occur as right lobe lesions. Prevalence of incidentalomas
foundby PET/CT atour institution is 1.84%, whichis within
the range of 1.2–4.3% reported by Liu [4]. The results of
our study are compared to studies done on incidentalomas
at other institutions (Table 3).The investigations at vari-
ous hospitals mentioned in Table 3 reﬂect diﬀerent study
designs, patient populations, and institutional practices. The
prevalence of incidentalomas range from 1.1% to 7% and
the prevalence of malignancy among incidentalomas ranges
from 14% to 66%.
A new thyroid nodule appears at the rate of 0.08%
p e ry e a ri nt h eg e n e r a lp o p u l a t i o n[ 22], and the incidence
of thyroid malignancy is 0.004–0.1% per year [2]. Not
surprisingly, the incidence and prevalence of thyroid cancer
in the patient population we see at the Nuclear Medicine
Department at UCSF is much higher than the general
population. If we perform PET/CT scans to screen for
incidentalomas in the general population, it will increase
the health care costs with little beneﬁt to the patients.
The cost of PET/CT far outweighs the reduced mortalityInternational Journal of Molecular Imaging 5
Table 3: The results of studies on incidentalomas at diﬀerent institutions.
Author No. PET studies No. incidentalomas No. biopsied Prevalence of malignancy
Cohen et al. [2] 4525 102 (2.3%) 15 (15%) 7 (47%)
Kang et al. [5] 1330 29 (2.2%) 15(52%) 4 (27%)
Chen et al. [7] 4803 60 (1.2%) 50 (83%) 7 (14%)
Ishimori et al. [8] 1912 79 (4.1%) 32 (41%) 6 (18%)
Kim et al. [3] 4136 45 (1.1%) 32 (71%) 16 (50%)
Are et al. [9] 8800 263 (2.9%) 57 (22%) 24 (42%)
Yi et al. [10] 140 6 (4.3%) 6 (100%) 4 (66%)
Choi et al. [11] 1763 70 (4%) 49 (70%) 18 (37%)
Nam et al. [12] 689 19 (2.8%) 12 (63%) 5 (42%)
Bogsrud et al. [13] 3347 79 (1.2%) 48 (61%) 17 (35%)
Wolf et al. [14] 185 13 (7%) 13 (100%) 7 (54%)
Chu et al. [15] 6241 76 (1.2%) 13 (17%) 4 (28%)
Bae et al. [16] 3379 285 (8.4%) 99 (35%) 22 (23%)
UCSF 8464 156 (1.8%) 40 (26%) 15 (38%)
associated with early diagnosis of thyroid cancers. A paper
by Ohba et al. [19], who prospectively followed patients
for 3 years, mentioned that repeated FDG-PET to follow
up patients with thyroid nodules is ineﬀective. Diﬀuse-
type incidentalomas with the absence of risk factors can be
managed by physician visits, lab tests, and monitoring with
US. Yet, we cannot rule out malignancy based on the diﬀuse
pattern alone because the diﬀuse uptake can mask the focal
lesions [3].
5. Limitationsof the Study
Prospective, multicenter analysis would be needed to elabo-
rate a more uniform guideline. One of the limitations of our
study is that out of 156 abnormal PET/CT thyroid exams,
only 40 had biopsy reports. The prevalence of malignancy
among incidentalomas may be diﬀerent from the current
one if all underwent biopsy. We must be aware that PET/CT
cannot detect small lesions such as micropapillary thyroid
carcinomas which can have normal or low SUV uptake [23].
6. Conclusion
Our data suggest that focal FDG uptake representing inci-
dentalomas should be followed by pathologic diagnosis,
especially in those with chronic conditions or known di-
agnosis of a solid tumor. This study did not support the
idea for using PET/CT to screen the general population for
incidentalomas.
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